Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

May 27, 2023

Study Completion Date

May 27, 2023

Conditions
Type 2 Diabetes Treated With Insulin
Interventions
DRUG

Insulin glargine

Insulin glargine doses will be determined by calculating the total daily dose (TDD) of insulin and providing 50% of the TDD as follows: start at 0.5 units/kg/day and subtract 0.1 unit/kg/day for 70+ yrs of age, renal insufficiency, pancreatic deficiency and add 0.1 unit/kg/day if hemoglobin A1c in \>10%

DRUG

NovoLog

Novolog will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.

DRUG

Insulin Fiasp

Fiasp will be administered with each meal if premeal glucose is ≥ 150 mg/dL and at bedtime if glucose is ≥ 200 mg/dL by calculating an individualized insulin sensitivity factor for each subject per the following formula: 1500/total daily dose of insulin = sensitivity factor.

OTHER

Standard carbohydrate diet

Standard carbohydrate diet as per usual hospital care (75g with each meal)

Trial Locations (1)

02118

Boston Medical Center, Boston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Boston Medical Center

OTHER